Search results

Kowa Pharmaceutical Europe AG is part of the Kowa Group, a global enterprise founded in 1894. Backed by over 130 years of innovation and expertise across pharmaceuticals, life sciences, trading, and manufacturing, we create value through quality, trust, and a worldwide network.

Memorises Bio is a therapeutic antibody discovery company spun out of Memo Therapeutics. We investigate human immune responses and translate them into therapeutic antibodies, combining deep repertoire capture with large-scale functional screening.

Based in Epalinges, Pilatus Biosciences focuses on developing a first-in-class antibody targeting metabolic checkpoints. The company is transforming cancer treatment by developing innovative therapies that strengthen the immune system to fight cancer.

We bring the most sensitive biophysical assays to the high-throughput screening world. Our integrated biophysics platform combines lab automation with on-the-fly data analysis, allowing our customers to screen up to a million compounds within weeks, harnessing the power of direct binding assays.

Step Pharma is a clinical stage precision oncology company. Dencatistat (STP938) is a first in class, oral, selective CTPS1 inhibitor currently in Phase I/II clinical development in essential thrombocythemia, biomarker selected solid tumours and relapsed/refractory lymphoma.

nuantic offers AI-guided lead optimization to biotech and pharma customers developing protein- and peptide-based therapeutics. We're able to optimize affinity, developability and aspects of immunogenicity with outstanding success rates with 10x less effort as compared to traditional methods.

FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which  moved into clinical Phase 1 in H2 2025.

arcoris bio develops next-generation technologies for biomarker detection in research and diagnostics. Its flagship MUSE platform provides universal, programmable signal amplification to enable highly sensitive and multiplex assays that drive the future of digital pathology.

Humion is a Swiss cancer therapeutics biotech developing TCR-based T-cell therapies for solid tumors. We decode the immune responses of cancer super responders to identify validated tumor targerts and translate them into precise, patient-derived therapeutics.

Solvias is a Contract Research, Development & Manufacturing Organization We offer comprehensive, high quality and fast analytical services for small molecule API, biologics and cell & gene therapies, by ensuring the interplay of outstanding experts in every required individual discipline.

dEEGtal develops AI-driven solutions to enhance EEG analysis, starting with a medical device for epilepsy diagnosis. While focused on clinical applications, we are expanding to offer AI models that provide deeper insights into EEG data for neuroscience, pharma, and industry partners.

ADM is a global leader in both human and animal nutrition. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow.

We are a seed-stage biotech company dedicated to relentlessly pursuing functional cures for rare disease patients and their families. With an initial focus on rare diseases, we aim to expand our scope to include genetically defined common diseases in the future.

Jantar is a clinical R/D company in the field of chronic rhinosinusitis. Its asset is dicholine succinate for which clinical proof-of-concept has been established. DISU represents a differentiated new drug with strong safety, rapid efficacy and clear potential for global consumer health leadership.

We offer state‑of‑the‑art, ready‑to‑use laboratories dedicated to research and scientific projects. Located close to office spaces, our ecosystem sits in the heart of Basel, one of Europe’s most dynamic scientific hubs.

Hemastatx brings innovation to patients with severe, underserved bleeding conditions. HMX-001 is a first-in-class anti-ADAMTS13 antibody targeting the root cause of severe bleeds in (rare) von Willebrand factor (VWF) disorders. Hemastatx is a KU Leuven spinoff and part of the BaseLaunch portfolio.

Preclinical stage biopharmaceutical company, spin off of the European Diabetes Study Center (CeeD), dedicated to developing first-in-class biotherapies against diabetes and metabolic diseases, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach

Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. We developed a new generation of protease inhibitors with enhanced potency and safety, exhibiting all the qualities needed to become first-in-class drugs for the treatment of cancer, autoimmune diseases and bone diseases.

Enabling breakthrough medicines achieve the outcomes they were designed for. We unlock the full therapeutic potential of innovative drug candidates through our next-gen nanomedicine delivery platform. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.

Minaris is a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization. With more than 25 years of CGT development and manufacturing expertise and more than 40 years in biosafety testing, Minaris combines deep legacy experience with state-of-the-art GMP facilities.

Alp Bio AG is a Swiss biotech startup that combines human immune organoid technology with generative AI. The company provides immunogenicity intelligence to detect and mitigate anti-drug antibody (ADA) risks years before clinical trials, helping developers avoid costly late-stage failures.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

We are a small CRO providing highly tailored services to customers with clinical trials and regulatory consulting needs. With expertise in drug, food supplements, medical devices, diagnostics and software, we support you at every stage of product's lifecycle, from preclinical development to market.

Opterion Health AG is a privately owned, Swiss-based, clinical-stage biotech company developing innovative therapies for peritoneal dialysis (PD).

Asemblis is a Swiss biotech company developing scalable, human-relevant in vitro models for obesity and metabolic disorders. The company partners with industry and research organizations to support translational R&D and decision-making in drug development.

Nanolynx Biologics AG is developing first-in-class conditionally active nanobody-drug conjugates (CA-NDCs) that overcome the tissue penetration and toxicity limits of conventional ADCs, enabling safer and more efficacious therapies for hard-to-treat solid tumors.  

AzureCell is a Swiss regenerative cell therapy company leveraging two decades of pioneering neuroscience and cell‑engineering research at the University of Geneva to advance next‑generation allogeneic cell‑replacement therapies for the brain.

GlioCART is a University of Basel spin-off focused on translating a dual-action CAR-T therapy for glioblastoma into clinical application by combining tumor targeting with immune microenvironment reprogramming. Our mission is to achieve durable clinical benefit for patients with glioblastoma.

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

Swiss Rockets is dedicated to developing groundbreaking medicines that transform the treatment of cancer, infectious diseases, and autoimmune disorders – advancing more effective, equitable, and accessible healthcare for patients worldwide.

CALDRE is a Switzerland based biotech spin-out focussed to revolutionize the way cholestatic-and fibrotic diseases are treated. We develop precise, liver-directed GalNAc-siRNAs to restore bile flow and prevent fibrosis - placing CALDRE in the fast-growing RNA-therapeutics segment of biotech.

RC TRITEC is an established company offering custom synthesis of tritium-labeled compounds, a range of tritiated catalog products, storage service and disposal of radiochemicals. We have over 60 years of experience in the safe handling of tritium gas using in-house developed high-vacuum equipment.

MoleSense is a multi-award-winning developer of medical wearable technologies. We are creating a new standard for continuous, non-invasive molecular monitoring, turning the body’s chemistry into real-time insight that transforms how health is predicted, prevented, and managed.  

SYDRA AG (Zurich) is a longevity biotech using a phenotype-first, AI-assisted “Hit-to-Target” early drug discovery platform. We discover small molecules (geroprotectors), validate in vivo (worms – aged mice), then map MoA to build partner-ready drug assets; plus science-backed supplements.

Topadur Pharma AG (Schlieren, Zurich) is a clinical-stage biotech company developing small-molecule therapies that target impaired microcirculation and tissue regeneration. Its proprietary DualTOP® platform combines complementary pharmacological activities in single molecules for local use.

Looking for cheap lab space in Basel? Lambda Biolab (a service of Mackenzie-Lamb Consulting) offers affordable, fully equipped BSL-1 benches for researchers and biotech entrepreneurs for a fraction of the cost of traditional labs. Reduced rates for students, artists, and non-profits are available.

Mabylon is a clinical-stage company leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Enantios is a Swiss startup revolutionizing molecular characterization with in-solution structural analysis of chiral complex molecules and biologics. Enantios delivers solutions for quality control and drug development in pharmaceutical, biotech, and chemical industries.

AND Biotech is a science-led company developing bioactive technologies that target the core systems of human resilience. We take promising compounds and translate them into clinically meaningful interventions. We develop scalable technologies that address biological decline, starting long before disease.

Antion’s mirGE™ platform enables precise multiplex gene silencing with synthetic miRNAs, allowing independent modulation of up to 7 targets in a single step. Compatible with viral and non-viral delivery, it is designed for scalable, safe and effective ex vivo and in vivo therapies and R&D models.

AxCellerate is a Swiss BioTech company offering pre-clinical research services through its organ-on-chip technologies, using proprietary systems and human-derived cells to to mimic the complexity of the central and peripheral nervous system.

CMC & More delivers hands-on CMC, regulatory, and quality expertise for biotech and pharma. We bridge discovery to first-in-human trials and beyond with GMP-compliant CMC strategies that derisk development and transform complex products into approval-ready assets.

DiNABIOS bridges the gap "from lab to life." We offer human-based screening, phenotyping, and services across diverse tissues. Using proprietary 3D tissue engineering and our DiNAQUBE™ platform, we deliver precise efficacy and safety data to de-risk drug development and accelerate clinical success.

At Lederer & Partner AG, we transform complex visions into clear successful results. Our expertise in engineering, construction, commissioning, qualification, and operation, we develop project models that are precisely aligned with your goals. As your trusted partner, we deliver lean, efficient solutions.

Ultimate Medicine is a Swiss preclinical biotech focused on preserving independence and quality of life for patients with Alzheimer's disease and other dementias.

EVIIVE develops single extracellular vesicle-based diagnostics to predict immunotherapy response and monitor tumor microenvironment in real time. Our platform integrates advanced flow analytics and machine learning for precision oncology applications.

TheraPPI Bioscience is a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases, and inflammation.  

Most cell and stem cell therapies fail beyond blood cancers because delivery cannot preserve function in solid organs. ClexBio’s biological platform enables safe, durable solid tissue replacement, unlocking regenerative therapies for liver failure, type 1 diabetes, and heart disease.

The Future Rewritten: Unlocking Genome Editing. By fusing directed evolution, high-throughput characterization, and AI, Nerai creates novel CRISPR editors, more precise and more powerful, making gene editing safer and accessible to more patients.

Tridek-One is a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

Immitra Bio is a pre-seed stage therapeutic biotech company spun out of ETH Zürich. Immitra Bio is developing a platform for scalable, curative in vivo gene-editing therapies.

Beech Biotech is developing a novel treatment for preeclampsia, an severe unmet medical need that takes the lives of 70,000 women and 500,000 babies each year. The company is developing a novel placenta-impermeable antibody and works with a network of expert industry consultants and contractors.

XEMPERIA, a spin-off from the University of Fribourg, is pioneering a groundbreaking approach to blood testing that leverages the body's immune response to detect breast cancer at its earliest and most treatable stage.

Umlaut.bio develops first-in-biology small molecules focusing on tRNAs that protect signalling transduction mRNAs from degradation. Addressing this previously undrugged fundamental biochemical principle  could be able to selectively prevent the growth of cancer as well as  proinflammatory cells.

Parithera is pioneering an AI-ready, clinical-grade liquid biopsy platform for single-cell analysis. Our platform is ideally positioned to study cancer treatment resistance.

MicThera harnesses microbes to discover breakthrough therapeutics, leveraging microbial bioactive molecules -synthetically produced- to overcome therapy resistance. Our discovery platform unlocks microbial-inspired therapeutics to develop innovative treatments.

Devintec Pharma is focused on B2B partnerships through out-licensing innovative substance-based medical devices. We apply DevinPro™ technology, that addresses root causes and creates a protective barrier for lasting relief, to our patended products in gastroenterology, dermatology, and gynecology.

Cure Pharma specializes in clinical supply management, including global supply chain coordination, comparator sourcing, logistics, and innovative labelling solutions. With a strong network and regulatory expertise, we ensure efficient, compliant, and reliable supply solutions for clinical studies.

At FloBiotech, we develop advanced human brain cell models to unlock new therapeutic and diagnostic pathways for neurodegenerative diseases. We address neurodegeneration at its core to enable earlier risk reduction in drug development, improved translational success, and scalable pipeline expansion.

CellX Biosolutions is a Swiss startup developing bacteria-based solutions to destroy PFAS and other persistent pollutants in water and soil. We discover and optimize rare bacterial degraders to build scalable, sustainable alternatives to costly incineration of chemical waste.

A swiss-based company developing therapeutics for chronic inflammation. We are engineering novel bi-functional Duokine therapeutics, rationally designed to simultaneously target distinct immune cell populations and disease-relevant pathways.

Nxera Pharma is a tech-driven biopharma company focused on specialty medicines for unmet needs in Japan and globally. With 30+ active programs in neurology, GI, immunology, metabolic, and rare diseases, Nxera employs 350+ people across Japan, the UK, Switzerland, and South Korea.

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. The company targets validated biology in respiratory and dermatology.

DiNAMIQS is a leading, science-driven end to end CDMO for AAV and Lentiviruses with a brand new GMP facility in Schlieren/ Zurich for up to 1000L manufacturing up to commercial including fill & finish.

TransHeps specializes in iDILI causality assessments, supporting drug developers in clinical trials and managing drug-induced liver injuries. Leveraging cutting-edge expertise, we provide reliable solutions to improve drug safety and accelerate pharmaceutical innovations.

Our single-use bioreactor simplifies and accelerates cell culture with automation and closed systems, accommodating volumes from 30 mL up to 30 L in the same vessel. Designed for a broad range of cells and for the entire product lifecycle (clinical research, process development, manufacturing).

Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech advancing immunotherapy via metabolic reprogramming. Its META 10 platform reverses T-cell exhaustion to unlock unprecedented efficacy and durability in oncology and autoimmune diseases, delivering a highly effective, scalable, and accessible approach.

Philip Morris International (PMI) is a leading international tobacco company with the objective to replace cigarettes with smoke-free products. The goal is to offer adult smokers, who would otherwise continue to smoke, better alternatives that are scientifically substantiated.

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators.

Abbmira Therapeutics is a Basel-based biotech founded by experienced scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

We "think data" and "speak biology", partnering with our clients to transform lives. Our team combines deep biological knowledge with proven expertise in AI & bioinformatics to tackle complex data challenges. Via our AI-native Bio|Verse platform, we accelerate biomarker discovery & drug development.

At CxO, we drive biotech startups toward growth by optimizing resource management and operational efficiency. As partners, we empower firms to innovate and scale. Our veteran team offers strategic insights to accelerate timelines, optimize ROI, and enhance workflows, ensuring client success.

InVirtuoLabs is pioneering the next-generation laboratory by integrating AI with molecular simulations to revolutionize drug discovery. Our platform generates up to 1 billion novel molecules per day, rapidly screening and identifying the most promising ligands for specific biological targets.

Avenza Consulting has been created to support pharma, biotech companies, startups to develop and grow by offering Strategic Consulting, R&D services to foster innovation, Program & Portfolio Management to optimize projects, and Operational Excellence to streamline processes.

Signal26 Biotherapeutics is a biotechnology startup dedicated to advancing a novel antibody for treating psoriasis. In collaboration with interdisciplinary experts, we lead research into interleukin 26 (IL-26) and its role in the signalling pathways involved in autoimmune disorders.

Precise Health develops AI-powered platforms for bacteriophage discovery, host-matching, and engineering. We serve hospitals, biotech, and pharma in the $50B+ anti-infectives and diagnostics markets, addressing the urgent global threat of antimicrobial resistance.

Juvion develops advanced therapeutics aimed at preserving neuron-muscle connectivity, tackling immobility and sarcopenia to extend healthspan.

We provide a portfolio of models for efficacy pharmacology in autoimmunity, immuno-oncology, and transplantation. Our humanized mouse and tumor xenograft platforms enable translational evaluation of biologics, cell therapies, and innovative immunotherapies.

Release Therapeutics SA (RTx) is a Swiss biotech company developing the first intracerebral encapsulated cell technology (ECT) platform for the treatment of severe genetic disorders of the central nervous system (CNS).

Enzene is a fully integrated CIDMO with sites in Pune (India) & New Jersey (USA), offering discovery to commercial supply. Its EnzeneX™ FCCM™ tech leads next-gen biologics, aiming to cut mAb costs below $40/g by 2025. Learn more at www.enzene.com.

BeOne Medicines is a global oncology company developing innovative, affordable, and accessible cancer treatments worldwide. We expedite development of our diverse pipeline of novel therapeutics through strong internal capabilities and collaborations. Our 11,000 colleagues span six continents.

Skyvor Medical is a Basel-based digital health company, founded by seasoned professionals with 35 years of drug development experience in global pharma. Skyvor Medical develops AI-powered digital platforms to accelerate the protocol design, feasibility and data management in clinical trials.

Founded in mid-2022, T-Oncology is a Swiss biotech startup dedicated to transforming cancer treatment through innovative therapies. Our Mission: Give hope to patients by creating advanced therapeutics that offer safe and more effective treatment options, affordable for patients worldwide.

Amporin is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral drugs to stop and reverse the progression of deadly degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease.

Procavea Biotech is an ETH Spin-off company developing an innovative protein-based RNA delivery platform. Our focus is to generate siRNA therapeutics in extrahepatic disease areas that are currently unreachable.

Prasfarma is a Pharmaceutical Company that operates as a CMO and CDMO) with experience in cytostatics, high potency products and biologics. Our flexibility & state of the art technologies, make us the ideal partner for small productions or R&D projects (pilot plant) and commercial supply (factory).

Cradle’s mission is to make engineering biology easier, quicker and more cost-effective. Its enterprise-grade AI software helps scientists engineer better proteins, faster and more successfully, speeding up the development cycle of new therapeutics and bio-based products. Learn more at cradle.bio.

Chelonia  is a Swiss innovation and AI strategy firm designing data-driven frameworks that translate scientific knowledge into real-world solutions. We integrate complex biological, clinical, and environmental data into deployable and explainable systems.

Allegria Therapeutics was founded in Basel in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases.

Complyomics supports Life Sciences companies in core areas as: Build and maintain robust Quality Systems in compliance with regulatory requirements. Provide externalized QA. Audits Develop expertise in Bioanalytical / Analytical areas Identify / assess / supervise sub-contractors Due diligence

Tandem Therapeutics (Spin-off ETH Zurich & PSI) is tackling the growing unmet medical need in treating fibrosis with precision extracellular matrix targeting. Our novel peptide drug conjugates selectively target mechanical changes in the fibrotic extracellular matrix to potentially halt progression.

ARTBIO is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) to transform cancer treatment. ARTBIO's approach centers on utilizing the alpha-emitting isotope Pb212 to target cancer cells while minimizing damage to healthy tissues.

NanThermix SA is a pioneer in nanoscale temperature control within living cells for applications across life sciences, from academic research to biomedical fields, based on a novel technollogy of all-optical nanodiamond heater / thermometer.

HekeTiss, a UNIGE/HUG spin-off, enhances lives by pioneering cell-therapy treatments for ulcerative skin conditions. Innovating for a healthier tomorrow.